Impact of Patents on Indian Pharma Industry's Growth and Competency: A Viewpoint of Pharmaceutical Companies in India

Journal of Intellectual Property Rights (Impact Factor: 0.34). 09/2009; 14(5):432-436.


Instruments of intellectual property rights (IPR) are considered to achieve economic, social and technological advancement for a country in all aspects. Of all the instruments of IPR, patent is the most contentious issue which is deliberated in several international fora. Patents are mostly debated for their role in pharmaceutical field. India signed General Agreement on Tariffs and Trade (GATT) in 1994 agreeing to implement the IPR in all fields of technology, including product patent, with effect from 1 January 1995. Taking into account India’s status as a developing country, India was granted a transition period of ten years from 1995 to 2005 to switch over from process patent to product patent. With this shift, it was imperative for Indian pharmaceutical companies to embrace product patents. This study was undertaken with the objective of identifying the situation in India after product patent regime was implemented. The role of Indian pharmaceutical companies in the era of product patent is crucial. The authors attempted to identify how Indian pharmaceutical companies view product patent regime, hindering the growth of industry or providing impetus to R&D, in this study. The measures taken by these companies to survive and grow in product patent regime have also been analysed

Download full-text


Available from: Nayanabhirama Udupa
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the context of recent amendments to the Indian Patent Act and introduction of the product patent, the present paper attempts to examine the innovative efforts of Indian pharmaceutical companies in the new patent regime. The paper finds that although R&D expenditure has increased significantly in the current decade, the increasing R&D efforts are not widespread across the firms and more than half of the Indian pharmaceutical companies do not spend at all on in-house R&D. This means that protection of intellectual property alone is not enough to encourage the firms towards innovation. Instead, it is observed that R&D expenditure varies directly the with market size of the firms, their capital intensity, exports orientation and past profitability, but inversely with their market share, selling efforts and import intensity. However, a firm's involvement in mergers and acquisition or sourcing of technology from foreign sources or variability in financial performance does not have any significant impact on its R&D efforts. Hence, the policy measures should be directed towards restricting the monopoly power of firms, encouraging exports, liberalizing imports of necessary machinery and equipment, and motivating the firms towards innovation, especially in life-saving drugs, an through appropriate incentive/disincentive structure.
    Full-text · Article · Nov 2010 · South East European Journal of Economics and Business
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patents, which are regarded as important sources of innovation, are closely related to innovation strategies, and data from patent registrations are frequently used in innovation studies. Generally, such studies collect patent information from a patent database and analyze it to identify innovation trends and strategies at the firm, industry, and national levels. Therefore, it is important not only to develop and apply a suitable analysis method, but also to select a patent database that is appropriate for such studies' research objectives. But few previous studies on patent analysis have carefully examined the suitability of the databases they have used.
    No preview · Article · Feb 2015 · Technological Forecasting and Social Change